Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03322657 · ClinicalTrials.gov registry record · Phase 4

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

A Phase 4 study of Anesthesia and Neuromuscular Blockade, sponsored by The Cleveland Clinic.

Completed
Registry status
Phase 4
Development phase
69
Enrollment target
1
Study location

NCT03322657 is a Phase 4 study of Anesthesia and Neuromuscular Blockade that has completed, run by The Cleveland Clinic. The registered enrollment target is 69 participants, below the 109,409-participant average among 57 other Anesthesia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03322657, a Phase 4 study of Anesthesia and Neuromuscular Blockade, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
Phase 4
Development phase
69 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other half will receive Sugammadex.

Interventions

  • DRUG Sugammadex
  • DRUG Neostigmine
  • DRUG Glycopyrrolate

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2017-11-14
Est. Completion 2021-02-01
Phase Phase 4

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT03322657

The ClinicalTrials.gov registry entry for NCT03322657 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109,409-participant average among 57 other Anesthesia trials with a reported enrollment target (100% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Anesthesia appearing as the primary indexed condition, and to 3 interventions - of which Sugammadex is the first listed.

NCT03322657 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03322657 about?

NCT03322657 is a clinical study titled "Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular". The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other hal...

What is the current status of trial NCT03322657?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2017-11-14. Estimated completion is 2021-02-01.

What conditions does trial NCT03322657 study?

This clinical trial studies the following conditions: Anesthesia, Neuromuscular Blockade.

What interventions are being tested in trial NCT03322657?

The interventions under investigation include: Sugammadex (DRUG), Neostigmine (DRUG), Glycopyrrolate (DRUG).

Who is sponsoring clinical trial NCT03322657?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03322657 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anesthesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.